I think this AIM stock’s price could surge…but I am being patient

Amryt Pharma (LSE: AMYT) might just have the revenues to get its exciting pipeline assets to market now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The big pharmaceutical companies typically avoid developing drugs for rare diseases as the markets are small, and sales do not typically cover the costs. If a rare disease is not having treatments developed for it, then it is described as being an ‘orphan’.

Governments offer incentives beyond what is typically available such as tax credits, extended rights, and fast-tracking of applications to stop this happening, and smaller drug makers have stepped in.

Strength in numbers

After acquiring Aegerion, formerly a subsidiary of NASDAQ-listed Novelion Therapeutics, Amryt Pharma (LSE: AMYT) will be a significant player in the rare and orphan disease market. The coming together has united the lomitapide brands Lojuxta and Juxtapid, which treat an inherited cholesterol disorder, and brought Myalept and Myalepta, which treat leptin deficiency, into the fold.

Sales of Lojuxta in Europe, the Middle East, and North Africa grew by 23% in 2018, and Amryt hopes to use its expertise to drive Juxatapid sales just as hard in North and Latin America, with patent protection in place until 2028 in the EU, and 2027 in the US.

Applications for paediatric applications and other indications are also in process. Myalept/Myalepta is already licensed for the treatment of generalised lipodystrophy in the EU and US, and partial lipodystrophy in the EU with an application in process for the US.

Amryt has made a loss every year since listing. Normally I would run a mile but the revenues and cost synergies from the combined commercial portfolio could make a real improvement here, and support Amryt’s existing pipeline in getting to market.

Potential in the pipeline

Amryt’s lead development asset promotes wound healing when applied with dressings in patients with epidermolysis bullosa (EB), better than the dressing alone. Approval for partial-thickness wound treatment in Europe has been gained, and more applications could follow. The general wound market is much larger than anything Amryt has targetted before.

Also being developed for EB sufferers is a non-viral gene therapy platform that works to restore collagen production of skin cells in pre-clinical models with topical application. Now, this has been in-licensed from University College Dublin, but think of in-licensing as an acquisition where you only get the bits of a company that you want.

The underlying gene delivery technology, which is a special polymer that binds the gene and delivers it into cells, could have application in other disorders and could be a real game-changer.

Seeking approval

I’m just looking at this stage. At the moment we have 2018 numbers in dollars for Aegerion, reported numbers for Amryt in euros, and the deal itself is complicated (in part because Aegerion had filed for bankruptcy on the back of regulatory action). In addition, there is a partial US listing planned for this year.

What I want to see is the first quarterly report as a combined company. This should come in early 2020 and deliver updated numbers reported in a single currency, and give me the opportunity to see if the chances of getting the pipeline assets to market have indeed increased from a financial standpoint. There will also be a little more time to see if there are any skeletons in the closet that Amryt has bought.

You can be patient when making investment decisions.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »